Ianalumab plus eltrombopag extends time to treatment failure in primary ITP adults
Study tests ianalumab plus eltrombopag for adults with immune thrombocytopenia
This phase 3 randomized, double-blind trial in 152 adults with primary ITP and insufficient response to glucocorticoids found that ianalumab…
Adding ianalumab to standard therapy helped more adults with immune thrombocytopenia stay stable and avoid treatment failure compared to pla…
IVIG and platelet transfusions managed immune thrombocytopenia in a very preterm infant with intraventricular hemorrhage
A preterm baby with low platelets improved after IVIG and transfusions
This case report and literature review describes management of immune thrombocytopenia in a very preterm male infant born to a mother with i…
A very preterm male infant born to a mother with immune thrombocytopenia improved after receiving intravenous immunoglobulin and platelet tr…
This narrative review examines immune-mediated thrombocytopenia and thrombotic thrombocytopenic purpura conditions without specific intervention data or reported outcomes
Review of rare blood disorders offers general overview of treatment options
This narrative review explores immune-mediated thrombocytopenia and thrombotic thrombocytopenic purpura. No specific interventions, outcomes…
This narrative review discusses immune thrombocytopenia and related conditions without reporting new findings or specific patient outcomes.
Rituximab exposure is associated with serum sickness in patients with multiple sclerosis, nephrotic syndrome, or immune thrombocytopenia
Can taking Rituximab cause a severe allergic reaction that returns if you take it again?
This retrospective review analyzed 39 published case reports of patients with rituximab-induced serum sickness (RISS).
Taking Rituximab can trigger a delayed allergic reaction that returns in most patients if the drug is given again, so doctors must use extre…
Hetrombopag increases platelet counts in children with immune thrombocytopenia in phase 3 trial
A New Pill Helps Kids with a Rare Bleeding Disorder Avoid Crisis
A phase 3 randomized controlled trial in 88 children and adolescents with primary immune thrombocytopenia found hetrombopag significantly in…
For children with a stubborn immune bleeding disorder, a new oral medication offers a promising path to stable platelet levels and fewer tre…
Phase 2 trial finds mezagitamab increases platelet counts in adults with persistent or chronic ITP
Mezagitamab increased platelet counts in adults with chronic or persistent immune thrombocytopenia in this early trial
A multicenter, double-blind, randomized, placebo-controlled Phase 2 trial in 41 adults with persistent or chronic ITP found 91% of participa…
Mezagitamab helped 91% of adults with chronic low platelet counts reach target levels, while only 23% on placebo did so in this early trial.
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine
A single case shows leukemia can initially look like a different blood disorder
A case report describes one patient initially diagnosed with immune thrombocytopenia (ITP) who was later found to have chronic myelomonocyti…
A single case shows leukemia can initially look like a different blood disorder, so doctors must watch for hidden mutations when standard tr…
Huaiqihuang Granule Improves Bleeding in Childhood CITP: 71.74% Effectiveness vs 45.65% Placebo
Could a Traditional Chinese Medicine Help Children with Immune Thrombocytopenia?
In a 216-child RCT, Huaiqihuang Granule (HQH) showed superior efficacy over placebo in reducing bleeding severity and achieving platelet res…
A traditional Chinese medicine helped 72% of children with chronic immune thrombocytopenia reduce bleeding and boost platelet counts compare…
Questions about Immune thrombocytopenia
Can Rituximab cause serum sickness in patients with immune thrombocytopenia?
Yes, rituximab can cause serum sickness in patients with immune thrombocytopenia (ITP), with cases documented in both children and adults.
Full answer →